Startups
Tarveda Therapeutics takes a novel approach to cancer treatment by creating Pentarins™, which are miniaturized biologic drug conjugates uniquely designed to target, penetrate and treat solid tumors. Through the Pentarin platform, Tarveda develops therapeutics to address the limitations of current cancer therapies in solid tumors.
Overview
Location
United States, Massachusetts, Watertown
Employees
11-50
Total raised
$68M
Founded date
2011
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 27, 2016 | Series C round | $38M |
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 3, 2017 | Funding sets up proof-of-concept trial for Tarveda's lead Pentarin next year | Boosted by a fresh $30 million tranche of funding, Tarveda Therapeutics will start phase 2 trials of its lead drug for advanced neuroendocrine tumors and small cell lung cancer early next year, according to CEO Drew Fromkin. Tarveda is focu... |
| Feb 3, 2017 | Term Sheet — Friday, February 3 | IPO CHRISTMAS A few highlights from the debutante ball of world’s most secretive company, Snap Inc: Paid Content What you need to know about growing cyberattacks From ExtraHop Income: Snap is losing a ton of money, but revenue grew signific... |
| Feb 2, 2017 | Tarveda Therapeutics Raises $30 Million Series D | WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced the completion of a $30... |
| Feb 2, 2017 | Send in the Pentarins: Tarveda raises $30M Series D | On Thursday, the company announced a subsequent $30 million Series D, led by Versant Ventures, a first-time investor. Existing investors New Enterprise Associates, Novo A/S, NanoDimension and Flagship Pioneering also got on board. In a phon... |
| Feb 2, 2017 | Versant Ventures Leads $30 Million Series D for Tarveda Therapeutics | WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced the completion of a $30... |
| Feb 2, 2017 | NEA Joins $30 Million Series D for Tarveda Therapeutics | WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced the completion of a $30... |
| Jan 27, 2016 | Tarveda Therapeutics Secures $38M in Series C Financing | Tarveda Therapeutics, Inc., (formerly Blend Therapeutics), a Watertown, MA-based biopharmaceutical company, secured $38m in Series C financing. The round was co-led by new investor Novo A/S and existing investor New Enterprise Associates (N... |
| Jan 27, 2016 | Daily funding roundup - January 27, 2016 | Tarveda Therapeutics secured $38M; Branch Metrics received $35M investment; PitchBook raised $10M CosmosID, a bioinformatics company focused on microorganisms and infectious diseases, today announced it has closed $6 million in Series B fun... |
| Send in the Pentarins: Tarveda raises $30M Series D | In a past life, Tarveda Therapeutics was called Blend Therapeutics. Founded in 2012, the company’s pipeline was full of potential but it lacked a clear focus. It was, for lack of a better word, a blend of different scientific programs. By 2... |
Reviews 0
FAQ about Tarveda Therapeutics
When was Tarveda Therapeutics founded?
Tarveda Therapeutics was founded in 2011.
How much funding has Tarveda Therapeutics raised?
Tarveda Therapeutics has raised $68M in total across 2 funding rounds.
What funding rounds has Tarveda Therapeutics raised?
Parsers VC lists 2 funding rounds of Tarveda Therapeutics, among them a Series C round of $38M on Jan 27, 2016.
What has the press written about Tarveda Therapeutics?
Parsers VC has collected 10 articles mentioning Tarveda Therapeutics, among them “Funding sets up proof-of-concept trial for Tarveda's lead Pentarin next year” (Feb 3, 2017) and “Term Sheet — Friday, February 3” (Feb 3, 2017).
Is Tarveda Therapeutics still active?
Tarveda Therapeutics is probably closed: its latest activity on Parsers VC dates from Jul 6, 2021.